Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb (BMS) is planning to build a new large-scale biologics manufacturing facility in Cruiserath, Dublin, Ireland, which will produce multiple therapies for its growing biologics portfolio.
Subscribe to our email newsletter
The new 30,000m² facility, to be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant, will house six 15,000l bioreactors, purification area as well as office and laboratory space.
Initial funding to support the first phase of the project has been approved by the company’s board of directors.
Total cost of the new facility, expected to be finalized in the second half of 2015, would be around $900m to build and operationalize the company’s biologics manufacturing facility in Devens, Massachusetts.
Bristol-Myers Squibb chief executive officer Lamberto Andreotti said: "Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb’s future.
"For 50 years, Bristol-Myers Squibb has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability."
The new facility is expected to be operational in 2019 following which about 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the site.
Following completion, the new facility will increase the company’s biologics manufacturing capacity as well as play a major role in its global manufacturing network.
The company has a growing portfolio of approved and investigational biologic medicines across multiple therapeutic areas such as oncology, virology and immunoscience.